Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Grever

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Leukemia Research|September 4, 1999
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group StudyC Karanes, K J Kopecky, D R Head, et al.
Annals of Internal Medicine|April 15, 1989
Chronic lymphocytic leukemia: recommendationsB D Cheson, J M Bennett, K R Rai, et al.
American Journal of Hematology|November 1, 1988
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working groupB D Cheson, J M Bennett, K R Rai, et al.
Blood|July 1, 1994
HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3A A Scott, D R Head, K J Kopecky, et al.
Leukemia|July 14, 2012
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cellsA J Johnson, Y-Y Yeh, L L Smith, et al.
Blood|July 27, 1999
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group StudyC P Leith, K J Kopecky, I M Chen, et al.
Leukemia|February 1, 2012
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic featuresJ A Woyach, G Lozanski, A S Ruppert, et al.
Leukemia|April 30, 2004
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cellsD M Lucas, M E Davis, M R Parthun, et al.
Leukemia|February 25, 2015
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemiaJ Flynn, J Jones, A J Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemiaS D Gore, E K Rowinsky, C B Miller, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Leukemia Research|September 4, 1999
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group StudyC Karanes, K J Kopecky, D R Head, et al.
Annals of Internal Medicine|April 15, 1989
Chronic lymphocytic leukemia: recommendationsB D Cheson, J M Bennett, K R Rai, et al.
American Journal of Hematology|November 1, 1988
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working groupB D Cheson, J M Bennett, K R Rai, et al.
Blood|July 1, 1994
HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3A A Scott, D R Head, K J Kopecky, et al.
Leukemia|July 14, 2012
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cellsA J Johnson, Y-Y Yeh, L L Smith, et al.
Blood|July 27, 1999
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group StudyC P Leith, K J Kopecky, I M Chen, et al.
Leukemia|February 1, 2012
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic featuresJ A Woyach, G Lozanski, A S Ruppert, et al.
Leukemia|April 30, 2004
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cellsD M Lucas, M E Davis, M R Parthun, et al.
Leukemia|February 25, 2015
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemiaJ Flynn, J Jones, A J Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemiaS D Gore, E K Rowinsky, C B Miller, et al.
Pageof 10